Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197522 | 0.78 | CA1 (0.79) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL6733562 | 0.78 | CA1 (0.79) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL9151672 | 0.78 | CA1 (0.79) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL743735 | 0.78 | ESR2 (0.45) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL1436252 | 0.76 | DYRK1A (0.53) | CLK4DYRK1AKDM4EXDHKMT2A | |
| SCHEMBL450323 | 0.76 | — | — | |
| SCHEMBL28300293 | 0.76 | ESR2 (0.52) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL28890215 | 0.75 | CA1 (0.73) | ESR2CA12CA1CA2CA7 | |
| Iodide SCHEMBL28861996 | 0.75 | CA1 (0.73) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL14037485 | 0.74 | DYRK1A (0.53) | ESR2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | claimed |
| EP-1453825-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | claimed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | claimed |
| WO-2003045937-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | claimed |
| US-6166015-A | Pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 2000-12-26 | — | — | US | claimed |
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK | 2011-05-12 | — | — | US | disclosed |
| EP-2262499-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | University Health Network (CA) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009111868-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-17 | — | — | WO | disclosed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | MERCK SHARP & DOHME CORP. | 2008-03-13 | — | — | US | disclosed |
| EP-1483266-B1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-1131288-A1 | PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
| US-6166015-A | Pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000031032-A1 | PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | ESR2 676/4885CA12 4777/4885CA1 3563/4885 |
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | NPY4R, GPR119, GIPR | ESR2 1952/4885CA12 3673/4885CA1 4540/4885 |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | NPY5R, NPY1R, SSTR5 | ESR2 2995/4885CA12 1887/4885CA1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.